International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Significant role of nanotechnology in cancer and molecular genetics: An overview

Tansukh Barupal, Yashwant Sompura, Sakshi Sharma, Harshita Rajput, H Chayadevi, Shyam Sunder Meena, Budha Ram, Shweta Bhodiwal

S.B.K. Govt. P.G. College, Jaisalmer, Rajasthan, India; University College of Science MLS University Udaipur Rajasthan, India; Department of Botany, IIS, University, Jaipur, Rajasthan, India

Article Information

Volume / Issue3 / 1 (January-March 2022)
Pages41-44
AccessOpen Access

Publication Timeline

  • Received01 February 2022
  • Accepted16 February 2022

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Nanotechnology is the understanding and control of matter at the Nano scale, at dimensions between approximately 1 and 100 nanometres, where unique phenomena enable novel applications. 1 nanometre is equal to 1 * 10^ -9. Nanotechnology offers the means to target chemotherapy directly and selectively to cancerous cells and neoplasm, guide in surgical resection of tumours, and enhance the therapeutic efficacy of radiation-based and current treatment modalities. All of this can add up to decreased risk to the patient and an increased probability of survival. As cancer is becoming the leading cause of deaths day by day so we need a proper treatment for that severe situation. We have many way of cancer treatment like surgeries, chemotherapy, hormone and immunotherapy’s cell transplant etc. But nanotechnology have the ability to raise the strength and selectivity biological physical and chemical approaches to obtain cancer cell death as well as decreasing the collateral toxicity to non-malignant cells. In this process the cancer cells are increasingly targeted by the material on nanoscale by active and passive targeting with great accuracy. Here we will discuss about the nanotechnology for cancer treatment by target drug delivery.

Keywords

OncogeneNanoparticlesEndoscopy

References

  1. Shang guan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci. USA. 2006; 103:11838-43. [Google Scholar][Crossref]
  2. Chu TC, Marks JW III, Lavery LA, et al. Aptamer toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006; 66:5989-92. [Google Scholar][Crossref]
  3. McNamara JO II, Andrechek ER, Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnology. 2006; 24:1005-15 [Google Scholar][Crossref]
  4. Hansson M, Ringdahl J, Robert A, et al. An in vitro selected binding protein (Affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein. Immunotechnology. 1999; 4:237-52. [Google Scholar][Crossref]
  5. Gabizon A, Shmeeda H, Horowitz AT, et al. Tumour cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid PEG conjugates. Adv Drug Deliv Rev. 2004; 56:1177-92. [Google Scholar][Crossref]
  6. Leamon CP, DePrince RB, Hendren RW. Folate-mediated drug delivery: Effect of alternative conjugation chemistry. J Drug Target. 1999; 7:157-69. [Google Scholar][Crossref]
  7. Ross JF, Chaudhuri PK, Ratnam M. Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer. 1994; 73:2432-43. [Google Scholar][Crossref]
  8. Park EK, Lee SB, Lee YM. Preparation and characterization of methoxy poly (ethylene glycol)/ poly (-caprolactam) amphiphilic block copolymeric nanospheres for tumour-specific folate-mediated targeting of anticancer drugs. Biomaterials. 2005; 26:1053-61. [Google Scholar][Crossref]
  9. Quintana A, Raczka E, Piehler L, et al. Design and function of a dendrimer-based therapeutic nanodevice targeted to tumour cells through the folate receptor. Pharmacol Res. 2002; 19:1310-6. [Google Scholar][Crossref]
  10. Gabizon A, Horowitz AT, Goren D, et al. Targeting folate receptor with folate linked to extremities of poly (ethylene glycol)-grafted liposomes: In vitro studies. Bioconjugate Chem. 1999; 10:289-98. [Google Scholar][Crossref]
  11. Ohannesian DW, Lotan D, Thom as P, et al. Carcinoembryonic antigen and other glycoconjugates act as ligands for galectin-3 in human colon carcinoma cells. Cancer Res. 1995; 55:2191-9. [Google Scholar][Crossref]
  12. Zubieta MR, Furman D, Barrio M, et al. Galectin-3 expression correlates with apoptosis of tumour-associated lymphocytes in human melanoma biopsies. Am J Pathol. 2006; 168:1666-75. [Google Scholar][Crossref]
  13. Managit C, Kawakami S, Nishikawa M, et al. Targeted and sustained drug delivery using pegylated glycosylated liposomes. Int J Pharmacol. 2003; 266:77-84. [Google Scholar][Crossref]
  14. Bibby DC, Talmadge JE, Dalal MK, et al. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumour-bearing mice. Int J Pharmacol. 2005; 293:281-90. [Google Scholar][Crossref]
  15. Mitra A, Mulholland J, Nan A, et al. Targeting tumour angiogenic vasculature using polymer-RGD conjugates. J Control Release. 2005; 102:191-201. [Google Scholar][Crossref]
  16. Schiffelers RM, Koning GA, Ten Hagen TL, et al. Antitumor efficacy of tumour vasculature-targeted liposomal doxorubicin. J Control Release. 2003; 91:115-22. [Google Scholar][Crossref]
  17. Beekman KW, Colevas AD, Cooney K, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: Scientific rationale and study design. Clin Genitourin Cancer 2006; 4:299-302. 2006; 56:226-43. [Google Scholar][Crossref]
  18. Nielsen UB, Kirpotin DB, Pickering EM, et al. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta. 2002; 1591:109-18. [Google Scholar][Crossref]
  19. Park JW, Hong K, Kirpotin DB, et al. Anti-HER2 immunoliposomes: Enhanced efficacy attributable to targeted delivery. Clin Cancer Res. 2002; 8:1172-81. [Google Scholar][Crossref]
  20. Steinhauser I, Spankuch B, Strebhardt K, et al. Trastuzumab-modified nanoparticles: Optimization of preparation and uptake in cancer cells. Biomaterials. 2006; 27:4975-83. [Google Scholar][Crossref]
  21. Brissette R, Prendergast JK, Goldstein NI, et al. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel. 2006; 9:363-69. [Google Scholar][Crossref]
  22. Newton JR, Kelly KA, Mahmood U, et al. In vivo selection of phage for the optical imaging of PC-3 human prostate carcinoma in mice. Neoplasia. 2006; 8:772-80. [Google Scholar][Crossref]
  23. Scott JK, Searching for peptide ligands with an epitope library. Science. 1990; 249:386-90. [Google Scholar][Crossref]
  24. Landon LA, Zou J, Deutscher SL et al. Is phage display technology on target for developing peptide-based cancer drugs? Curr Drug Discov Technol. 2004; 1:113-32. [Google Scholar][Crossref]
  25. Kelly KA, Nahrendorf M, Yu AM, et al. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol. 2006; 8:201-7. [Google Scholar][Crossref]
  26. Pasqualini R, Koivunen E, Ruoslahti E. et al. TV integrins as receptors for tumour targeting by circulating ligands. Nat Biotechnology. 1997; 15:542-6. [Google Scholar][Crossref]
  27. Krag DN, Shukla GS, Shen GP, et al. Selection of tumour-binding ligands in cancer patients with phage display libraries. Cancer Res. 2006; 66:7724-33. [Google Scholar][Crossref]
  28. Savic R, Luo L, Eisenberg A, Maysinger D, et al. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science (New York, NY). 2003; International Journal of Medical and All Body Health Research www.allmedicaljournal.com 300:615-8. [Google Scholar][Crossref]
  29. Jones M, Polymeric micelles a new generation of colloidal drug carriers. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmaceutics Verfahrenstechnik eV. 1999; 48:101-11. [Google Scholar][Crossref]
  30. Sung JC, Pulliam BL, Edwards DA. et al. Nanoparticles for drug delivery to the lungs. Trends in biotechnology. 2007; 25:563-70. [Google Scholar][Crossref]
  31. Davis ME, Chen ZG, Shin DM, et al. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature reviews Drug discovery. 2008; 7:771-82. [Google Scholar][Crossref]
  32. Berry G, et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Annals of oncology: official journal of the European Society for Medical Oncology. 1998; 9:711-6. [Google Scholar][Crossref]
  33. Ewer MS, et al. Cardiac safety of liposomal anthracyclines. Seminars in oncology. 2004; 31:161-81. [Google Scholar][Crossref]
  34. Sharma G, et al. Liposomes as targeted drug delivery systems in the treatment of breast cancer. Journal of drug targeting. 2006; 14:301-10 [Google Scholar][Crossref]
  35. Fenske DB, et al. Liposomal nanomedicines. Expert opinion on drug delivery. 2008; 5:25-44. [Google Scholar][Crossref]
  36. Allen TM and Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Advanced drug delivery reviews. 2013; 65:36-48. [Google Scholar][Crossref]
  37. Immordino ML, et al. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. International journal of nanomedicine. 2006; 1:297-315. [Google Scholar][Crossref]
  38. Berger JL, et al. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. OncoTargets and therapy. 2014; 7:1409-13. [Google Scholar][Crossref]
  39. Chou H, et al. A tale of the two PEGylated liposomal doxorubicins. Onco Targets and therapy. 2015; 8:1719-20. [Google Scholar][Crossref]
  40. Kesharwani P, Iyer AK. Recent advances in dendrimer-based nanovectors for tumour-targeted drug and gene delivery. Drug discovery today. 2015; 20:536-47. [Google Scholar][Crossref]
  41. Bianco A, et al. Applications of carbon nanotubes in drug delivery. Current opinion in chemical biology. 2005; 9:674-9. [Google Scholar][Crossref]
  42. Brennan ME, et al. Nonlinear photoluminescence from van Hove singularities in multiwalled carbon nanotubes. Optics letters. 2003; 28:266-8. [Google Scholar][Crossref]
  43. Kam NW, et al. Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:11600-5 [Google Scholar][Crossref]

How to Cite

Barupal, T., Sompura, Y., Sharma, S., Rajput, H., Chayadevi, H., Meena, S. S., Ram, B., & Bhodiwal, S. (2022). Significant role of nanotechnology in cancer and molecular genetics: An overview. International Journal of Medical and All Body Health Research, 3(1), 41-44.

Barupal, Tansukh, et al. "Significant role of nanotechnology in cancer and molecular genetics: An overview." International Journal of Medical and All Body Health Research, vol. 3, no. 1, 2022, pp. 41-44.

Barupal, T., Sompura, Y., Sharma, S., Rajput, H., Chayadevi, H., Meena, S. S., Ram, B. and Bhodiwal, S. (2022) 'Significant role of nanotechnology in cancer and molecular genetics: An overview', International Journal of Medical and All Body Health Research, 3(1), pp. 41-44.

Barupal T, Sompura Y, Sharma S, Rajput H, Chayadevi H, Meena SS, et al. Significant role of nanotechnology in cancer and molecular genetics: An overview. International Journal of Medical and All Body Health Research. 2022;3(1):41-44.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.